^
    3d
    BGB-290-103: Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=139, Completed, BeiGene | Phase classification: P1b --> P1
    Phase classification • Metastases
    |
    AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    temozolomide • Partruvix (pamiparib)
    1m
    SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Peking University Shenzhen Hospital
    New P2 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • gemcitabine • Rozlytrek (entrectinib) • imatinib • 5-fluorouracil • Tyvyt (sintilimab) • Alecensa (alectinib) • Nerlynx (neratinib) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Irene (pyrotinib) • Balversa (erdafitinib) • albumin-bound paclitaxel • irinotecan • Orpathys (savolitinib) • epirubicin • vinorelbine tartrate • Partruvix (pamiparib) • Epkinly (epcoritamab-bysp) • Hetronifly (serplulimab) • Enweida (envafolimab) • Vumon (teniposide) • Ariely (adebrelimab)
    4ms
    Co-Targeting of DTYMK and PARP1 as a Potential Therapeutic Approach in Uveal Melanoma. (PubMed, Cells)
    In vitro tests on MP41 (BAP1 positive) and MP46 (BAP1 negative) cancer cell lines using inhibitors pamiparib (PARP1) and Ymu1 (DTYMK) demonstrated significant cytotoxic effects...Our hypothesis of the double hit into tumoral DNA metabolism as a possible therapeutic option in uveal melanoma was confirmed since combined targeting of DTYMK and PARP1 affected all tested cytophysiological parameters with the highest efficiency. Our in vitro findings provide insights into novel therapeutic avenues for managing uveal melanoma, warranting further exploration in preclinical and clinical settings.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    Partruvix (pamiparib)
    4ms
    Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Bai-Rong Xia | N=20 --> 37
    Enrollment change • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    4ms
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Recruiting, University of California, San Francisco | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial primary completion date • Combination therapy
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    temozolomide • Partruvix (pamiparib)
    5ms
    Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 16 substudy 37: Pamiparib (ACTRN12621001183875)
    P2, N=16, Terminated, The University of Sydney | Recruiting --> Terminated
    Trial termination
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit)
    |
    Partruvix (pamiparib)
    5ms
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    5ms
    ATM, BLM, and CDH1 gene co-mutations in a high-grade endometrial stromal sarcoma patient with multiple abdominal cavity metastases: a case report and literature review. (PubMed, BMC Geriatr)
    Due to the successful use of poly ADP-ribose polymerase inhibitor (PARPi) on HG-ESS, we suggest that the selection of effective targeted drugs combined with anti- programmed death-1 (PD-1) drug therapy based on genetic testing may become a new option for the treatment of homologous repair deficient (HR-deficient) HG-ESS.
    Review • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker • Stroma
    |
    CDH1 (Cadherin 1)
    |
    Focus V (anlotinib) • Tyvyt (sintilimab) • Partruvix (pamiparib)
    6ms
    Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors. (PubMed, Cancer Med)
    Pamiparib in combination with TMZ had a manageable safety profile. Further investigation of the efficacy of this combination in tumor types with specific DNA damage repair deficiencies is warranted.
    P1 data • Journal • Combination therapy • PARP Biomarker • Metastases
    |
    HRD (Homologous Recombination Deficiency) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    temozolomide • Partruvix (pamiparib)
    6ms
    BGB-290-AU-002: Phase 1a/1b BGB-290 for Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=101, Completed, BeiGene | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Partruvix (pamiparib)
    7ms
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
    8ms
    Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Bai-Rong Xia | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    8ms
    Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (clinicaltrials.gov)
    P2, N=40, Recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial • Metastases
    |
    cisplatin • docetaxel • Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • goserelin acetate • Airui'en (rezvilutamide)
    8ms
    Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (PubMed, Int J Gynecol Cancer)
    To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer. Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CD8 (cluster of differentiation 8)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Partruvix (pamiparib)
    8ms
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    10ms
    BGB-290-102: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=128, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Partruvix (pamiparib)
    10ms
    Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=40, Recruiting, Affiliated Hospital of Jiangnan University | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    Partruvix (pamiparib)
    10ms
    Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A) • CHEK2 (Checkpoint kinase 2) • RAD50 (RAD50 Double Strand Break Repair Protein) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CHEK1 (Checkpoint kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression
    |
    Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)
    11ms
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Suspended --> Completed
    Trial completion
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    11ms
    A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Zhejiang Cancer Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Partruvix (pamiparib)
    1year
    Advances in Development of Selective Antitumor Inhibitors That Target PARP-1. (PubMed, J Med Chem)
    The currently approved PARP inhibitors include olaparib, niraparib, rucaparib, talazoparib, fuzuloparib, and pamiparib. The present review introduces the necessity for research on the development of selective PARP-1 inhibitors from the perspective of structural and functional mechanisms of PARP-1 inhibition. A review of recently reported selective PARP-1 inhibitors provides the foundation for exploring novel strategies for designing selective PARP-1 inhibitors from the perspective of structure-activity relationships combined with computer simulations.
    Review • Journal
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    1year
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Suspended, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2023 --> Dec 2023 | Trial primary completion date: Oct 2023 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    1year
    Phase II and Phase 0 results of ABTC 1801: a multi-arm clinical trial of the PARP inhibitor pamiparib with very low dose metronomic temozolomide in recurrent IDH mutant gliomas (SNO 2023)
    While pamiparib appeared to achieve sufficient pharmacologically active concentrations in both enhancing and non-enhancing tumors, combination with temozolomide did not produce a meaningful ORR in IDHmt recurrent gliomas. Cumulative hematologic toxicity was substantial.
    Clinical • P2 data • BRCA Biomarker • PARP Biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 mutation
    |
    temozolomide • Partruvix (pamiparib)
    1year
    Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients. (PubMed, J Pharm Biomed Anal)
    In this study, we established and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) based method to simultaneously quantify the four frequently prescripted PARP inhibitors, namely niraparib, olaparib，fluzoparib, and pamiparib, in ovarian cancer. The mean plasma concentrations (±SD) of niraparib and olaparib were 424.76 (±228.35) ng/mL and 1760.47 (±1739.69) ng/mL, respectively. The validated LC-MS/MS method allows the convient and efficient determination of four PARP inhibitors' exposure levels in ovarian cancer patients.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Lynparza (olaparib) • Zejula (niraparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    1year
    Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. (PubMed, J Neurooncol)
    Our study identifies the combination of entinostat with olaparib as a new potential therapeutic approach for MYC-driven Group 3 MB.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC amplification
    |
    Lynparza (olaparib) • doxorubicin hydrochloride • Kisqali (ribociclib) • Xpovio (selinexor) • Partruvix (pamiparib) • idasanutlin (RG7388) • Jingzhuda (entinostat) • vinblastine
    1year
    PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. (PubMed, Semin Oncol)
    Currently, four agents, namely olaparib, rucaparib, niraparib, and talazoparib, have obtained approval in the United States and Europe. Additionally, this review briefly covers veliparib, a PARP inhibitor under development, and two recently approved PARP inhibitors in China, fuzuloparib and pamiparib. Although significant progress has been made in understanding PARP inhibitors, there are several unanswered questions that remain, necessitating further research across a broader spectrum of cancer types within this evolving class of anticancer agents.
    PK/PD data • Review • Journal • PARP Biomarker
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • veliparib (ABT-888) • Partruvix (pamiparib) • AiRuiYi (fluzoparib)
    1year
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Suspended, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting --> Suspended
    Trial suspension
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    1year
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    1year
    A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma. (PubMed, Int J Radiat Oncol Biol Phys)
    Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
    Journal • PARP Biomarker
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Lynparza (olaparib) • Partruvix (pamiparib)
    1year
    A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma (ASTRO 2023)
    Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.
    Clinical • PARP Biomarker
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    Lynparza (olaparib) • Partruvix (pamiparib)
    over1year
    Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. (PubMed, Br J Cancer)
    Pamiparib plus tislelizumab showed a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR in TNBC and was associated with a manageable safety profile.
    P1 data • Journal • Combination therapy • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)
    over1year
    Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study (ESMO 2023)
    Conclusions Pamiparib combined with Surufatinib as a new neoadjuvant "chemotherapy-free" regimen showed extremely high R0 and ORR rates with manageable toxicity profiles. Currently, the experiment is still ongoing and further analysis and reporting of more data will be conducted.
    Clinical • P2 data • BRCA Biomarker • PARP Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    over1year
    Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results. (PubMed, Cancer Med)
    Maintenance pamiparib did not meet statistical significance for superiority versus placebo for PFS, but was well tolerated with few treatment discontinuations; no unexpected safety signals were identified.
    P2 data • Journal • PARP Biomarker • Metastases
    |
    PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    Partruvix (pamiparib)
    over1year
    BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
    P1/2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Apr 2023 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    temozolomide • Partruvix (pamiparib)
    over1year
    BGB-290-103: Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=139, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    temozolomide • Partruvix (pamiparib)
    over1year
    FLASH radiotherapy and PARP inhibition on preclinical models of glioblastoma and neurotoxicity (ESTRO 2023)
    Material and Methods Mice were randomly allocated to the following groups: 1) control; 2) FLASH irradiation (FLASH IR, mean dose rate= 2000 Gy/s); 3) Conventional dose rate irradiation (CONV IR, 0.1 Gy/s); 4) PARP inhibitor (PARPi, pamiparib, oral gavage, 12.5 mg/kg, twice daily for 7 days); 5) PARPi+CONV IR; and 6) PARPi+FLASH IR...However, the combination of PARPi+CONV IR was also associated with increased acute systemic toxicity. Overall, this research demonstrates the potential of using FLASH radiotherapy together with PARP inhibitors for the treatment of glioblastoma.
    Preclinical
    |
    Partruvix (pamiparib)
    over1year
    Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Jonsson Comprehensive Cancer Center | N=21 --> 0 | Trial completion date: Aug 2024 --> May 2023 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    FH (Fumarate Hydratase)
    |
    temozolomide • Partruvix (pamiparib)
    almost2years
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, University of Chicago | Initiation date: Nov 2022 --> Nov 2023
    Trial initiation date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    almost2years
    Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report. (PubMed, Anticancer Drugs)
    Next, the patient had received targeted combination therapy with poly (ADP-ribose) polymerase (PARP) inhibitor pamiparib and bevacizumab, achieving partial remission. To date, the patient has been followed up for more than half a year with favorable survival and high quality of life. The case report suggested that parmiparib-targeted therapy is a viable treatment option for advanced OCCC patients with RAD50 mutation.
    Journal • PARP Biomarker • Metastases
    |
    HRD (Homologous Recombination Deficiency) • RAD50 (RAD50 Double Strand Break Repair Protein)
    |
    RAD50 mutation
    |
    Avastin (bevacizumab) • Partruvix (pamiparib)
    almost2years
    Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    tamoxifen • Partruvix (pamiparib)
    2years
    Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Bai-Rong Xia
    New P2 trial • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    2years
    Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. (PubMed, Breast Cancer Res Treat)
    Pamiparib showed encouraging efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2- breast cancer with gBRCA1/2 m.
    Clinical • P2 data • Journal • BRCA Biomarker • PARP Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • BRCA mutation
    |
    Partruvix (pamiparib)